The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Open accessAbstract
Background and Aims Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These functions normally contribute to tissue repair under homeostatic conditions, but sustained activation in chronic liver diseases drives fibrosis, especially in MASH (41) where they are detectable by expression of desmin and alpha smooth muscle actin (αSMA) using immunofluorescence, and by conservation of gene expression based on single-cell RNA-seq (42-46).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the FAT-MASH model was used, as this model reproducibly recapitulates the stages of progression of human MASH that include advanced fibrosis and tumors along with changes in the gut microbiome.14,33,34”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“Our laboratory uses a simple rodent model of MASH, the “FAT-MASH” mouse, which robustly develops Fibrosis and Tumors, features of advanced disease, after 24 weeks of a Western diet combined with a small weekly dose of the liver toxin CCl4 (45).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationMaeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160
Cited by
Sorted by citations
Items 101–200 of 587
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 53
Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet
Ganguly, S., Muench, G. A., Shang, L., Rosenthal, S. B., Rahman, G., Wang, R., Wang, Y., Kwon, H. C., Diomino, A. M., Kisseleva, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.010 · Cited by 50
Holland, C. H., Flores, R. O. R., Myllys, M., Hassan, R. A. R. A., Edlund, K., Hofmann, U., Marchan, R., Cadenas, C., Reinders, J., Hoehme, S., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1797 · Cited by 50
A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis
Xi, Y., LaCanna, R., N’Diaye, E.-N., Gierke, S., Ma, H., Caplazi, P., Sagolla, M. S., Huang, Z., Lucio, L., Arlantico, A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.009 · Cited by 51
Precision models in hepatocellular carcinoma
Bárcena‐Varela, M., Monga, S. P., & Lujambio, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01024-w · Cited by 57
Sircana, A., Paschetta, E., Saba, F., Molinaro, F., & Musso, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071745 · Cited by 46
Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
Zhou, J., Tripathi, M., Sinha, R. A., Singh, B. K., & Yen, P. M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.134 · Cited by 49
Tian, C., Min, X., Zhao, Y., Wang, Y., Wu, X., Liu, S., Dou, W., Zhou, T., Liu, Y., Luo, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.017 · Cited by 49
Zhao, Z., Deng, Z., Huang, S., Ning, M., Feng, Y., Shen, Y., Zhao, Q., & Leng, Y. (2022) · Nutrients · doi:10.3390/nu14122411 · Cited by 46
Yang, S., Duan, Z., Zhang, S., Fan, C., Zhu, C., Fu, R., Ma, X., & Fan, D. (2023) · Foods · doi:10.3390/foods12132492 · Cited by 45
Hwang, S., Ren, T., & Gao, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0100 · Cited by 43
Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 47
Signaling Nodes Associated with Endoplasmic Reticulum Stress during NAFLD Progression
Koo, J. H., & Han, C. Y. (2021) · Biomolecules · doi:10.3390/biom11020242 · Cited by 43
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 45
Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis
Chen, Y., & Tian, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01500 · Cited by 47
The Endless Sources of Hepatocellular Carcinoma Heterogeneity
Bárcena‐Varela, M., & Lujambio, A. (2021) · Cancers · doi:10.3390/cancers13112621 · Cited by 43
Liu, I.-F., Lin, T.-C., Wang, S., Yen, C., Li, C., Kuo, H., Hsieh, C., Chang, C.-Y., Chang, C., Chen, Y., et al. (2023) · Biology Direct · doi:10.1186/s13062-023-00363-z · Cited by 44
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40
AGK regulates the progression to NASH by affecting mitochondria complex I function
Ding, N., Wang, K., Jiang, H., Yang, M., Zhang, L., Fan, X., Zou, Q., Yu, J., Dong, H., Cheng, S., et al. (2022) · Theranostics · doi:10.7150/thno.69826 · Cited by 40
Biomarker discovery for chronic liver diseases by multi-omics – a preclinical case study
Veyel, D., Wenger, K., Broermann, A., Bretschneider, T., Luippold, A. H., Krawczyk, B., Rist, W., & Simon, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-58030-6 · Cited by 38
Autophagy in Hepatic Steatosis: A Structured Review
Ramos, V. D. M., Kowaltowski, A. J., & Kakimoto, P. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657389 · Cited by 42
Scagliola, A., Miluzio, A., Ventura, G., Oliveto, S., Cordiglieri, C., Manfrini, N., Cirino, D., Ricciardi, S., Valenti, L. V. C., Baselli, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25195-1 · Cited by 40
Ghallab, A., Myllys, M., Friebel, A., Duda, J., Edlund, K., Halilbasic, E., Vucur, M., Hobloss, Z., Brackhagen, L., Begher‐Tibbe, B., et al. (2021) · Cells · doi:10.3390/cells10102516 · Cited by 42
Suguro, R., Pang, X., Yuan, Z., Chen, S., Zhu, Y. Z., & Xie, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104519 · Cited by 39
Longo, L., Ferrari, J. T., Rampelotto, P. H., Dellavia, G. H., Pasqualotto, A., de Oliveira, C. P. M. S., Cerski, C. T. S., da Silveira, T. R., Cruz, C. U., & Álvares‐da‐Silva, M. R. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s262879 · Cited by 39
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
Karin, M., & Kim, J. Y. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13685 · Cited by 45
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 41
Li, J., Liu, M., Li, Y., Sun, D., Shu, Z., Tan, Q., Guo, S., Xie, R., Gao, L., Ru, H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01065 · Cited by 38
Wu, M., Sun, J., Wang, L., Wang, P., Xiao, T., Wang, S., & Liu, Q. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.130276 · Cited by 36
Wang, X., Zhen, W., Liu, Y., Wu, C., Jiang, J., Hashimoto, K., & Zhou, X. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106658 · Cited by 41
Pathogenesis of and major animal models used for nonalcoholic fatty liver disease
Jiang, M., Wu, N., Chen, X., Wang, W., Chu, Y., Liu, H., Li, W., Chen, D., Li, X., & Xu, B. (2019) · Journal of International Medical Research · doi:10.1177/0300060519833527 · Cited by 36
Mishra, A. K., Castañeda, T. R., Bader, E., Elshorst, B., Cummings, S., Scherer, P., Bangari, D. S., Loewe, C., Schreuder, H., Pöverlein, C., et al. (2020) · Advanced Science · doi:10.1002/advs.202002997 · Cited by 34
Borowa‐Mazgaj, B., de Conti, A., Tryndyak, V., Steward, C. R., Jimenez, L., Melnyk, S., Seneshaw, M., Mirshahi, F., Rusyn, I., Beland, F. A., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz110 · Cited by 36
Seubnooch, P., Montani, M., Dufour, J., & Masoodi, M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100599 · Cited by 39
Pan, Y., Wang, Y., Tang, W., Sun, W., Ma, Y., Lin, S., Jing, J., Jiang, L., Shi, H., Song, Z., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61473-6 · Cited by 35
Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis
Panera, N., Braghini, M. R., Crudele, A., Smeriglio, A., Bianchi, M., Condorelli, A. G., Nobili, R., Conti, L. A., Stefanis, C. D., Lioci, G., et al. (2022) · Nutrients · doi:10.3390/nu14183791 · Cited by 34
Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis
Mooring, M., Yeung, G. A., Luukkonen, P., Liu, S., Akbar, M. W., Zhang, G. J., Balogun, O., Yu, X., Mo, R., Nejak-Bowen, K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3157 · Cited by 33
Harris, S., Poolman, T. M., Arvaniti, A., Cox, R., Gathercole, L., & Tomlinson, J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00055.2020 · Cited by 35
Sharma, L., Gupta, D., & Abdullah, S. T. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.01.001 · Cited by 33
Tsouka, S., Kumar, P., Seubnooch, P., Freiburghaus, K., St–Pierre, M. V., Dufour, J., & Masoodi, M. (2024) · Communications Medicine · doi:10.1038/s43856-024-00465-3 · Cited by 37
Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis
Cheng, Q., Fan, J., Deng, X.-W., Liu, H., Ding, H.-R., Fang, X., Wang, J., Chen, C., & Zhang, W. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i41.6346 · Cited by 32
Tao, G., Liu, F., Jin, Z., Liu, B., Wang, H., Li, D., Tang, W., Chen, Y., He, Q., & Qin, S. (2023) · Theranostics · doi:10.7150/thno.80494 · Cited by 31
Fang, Q., Li, X., Wang, M., Qiao, X., Huang, F., Hu, C., Xue, Y., Zhao, S., & Lin, Y. (2022) · Food & Function · doi:10.1039/d2fo00012a · Cited by 31
Oates, J. R., Sawada, K., Giles, D. A., Alarcon, P. C., Damen, M. S. M. A., Szabo, S., Stankiewicz, T. E., Moreno‐Fernandez, M. E., & Divanovic, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1095132 · Cited by 30
Hu, Y., Bao, X., Zhang, Z., Chen, L., Liang, Y., Qu, Y., Zhou, Q. Y., Zhou, X., Fang, J., Xiao, Z., et al. (2024) · Theranostics · doi:10.7150/thno.91572 · Cited by 31
Maeso‐Díaz, R., Du, K., Pan, C. C., Guy, C. D., Oh, S., Chen, T., Wang, L., Ko, D. C., Tang, L., Dutta, R. K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000401 · Cited by 30
Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH)
Li, X., Bhattacharya, D., Yuan, Y., Wei, C., Zhong, F., Ding, F., D’Agati, V. D., Lee, K., Friedman, S. L., & He, C. (2023) · Kidney International · doi:10.1016/j.kint.2023.12.009 · Cited by 30
Self-citationJiang, K., Lu, S., Li, D., Liu, M., Hu, J., Lei, B., Wang, S., Long, K., He, S., & Zhong, F. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02002-w · Cited by 29
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges
Cigliano, A., Liao, W., Deiana, G. A., Rizzo, D., Chen, X., & Calvisi, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071624 · Cited by 32
Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R. B., Chen, L., Lightstone, A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx0368 · Cited by 47
Self-citationRomualdo, G. R., Silva, E. D. A., da Silva, T. C., Aloia, T. P. A., Nogueira, M. S., de Castro, I. A., Vinken, M., Barbisan, L. F., & Cogliati, B. (2019) · Environmental Toxicology · doi:10.1002/tox.22887 · Cited by 29
Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis
Hirsova, P., Böhm, F., Dohnalkova, E., Nožičková, B., Heikenwalder, M., Gores, G., & Weber, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2283-9 · Cited by 27
Nieves, A. S., Salas‐Silva, S., Chávez-Rodríguez, L., Escobedo‐Calvario, A., Desoteux, M., Bucio, L., Souza, V., Miranda-Labra, R. U., Muñoz-Espinosa, L. E., Coulouarn, C., et al. (2021) · Cancers · doi:10.3390/cancers13071721 · Cited by 30
Márquez-Quiroga, L. V., Arellanes‐Robledo, J., Vásquez-Garzón, V. R., Villa‐Treviño, S., & Muriel, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114845 · Cited by 29
Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application
Liu, S., Huang, F., Ru, G., Wang, Y., Zhang, B., Chen, X., & Chu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.902820 · Cited by 29
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Self-citationKLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7
Yang, S., Jia, L., Xiang, J., Yang, G., Qiu, S., Kang, L., Zheng, P., Liang, Z., & Lü, Y. (2022) · EMBO Reports · doi:10.15252/embr.202154229 · Cited by 28
Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Li, Y., Qi, P., Song, S., Wang, Y., Wang, H., Cao, P., Liu, Y., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116585 · Cited by 28
Rodent model of metabolic dysfunction‐associated fatty liver disease: a systematic review
Cui, X., Li, H., Li, L., Xie, C., Gao, J., Chen, Y., Zhang, H., Hao, W., Fu, J., & Guo, H. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16749 · Cited by 27
Stress of Strains: Inbred Mice in Liver Research
Rogers, A. B. (2018) · Gene Expression · doi:10.3727/105221618x15337408678723 · Cited by 27
Dreval, K., Tryndyak, V., de Conti, A., Beland, F. A., & Pogribny, I. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00486 · Cited by 27
Protective Property of Scutellarin Against Liver Injury Induced by Carbon Tetrachloride in Mice
Miao, Z., Lai, Y., Zhao, Y., Chen, L., Zhou, J., Li, C., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.710692 · Cited by 27
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111524 · Cited by 27
FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
Zhang, L., Zhang, Q., Teng, D., Guo, M., Tang, K., Wang, Z., Wei, X., Li, L., Zhang, X., Wang, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202301166 · Cited by 25
Jiang, W., Zeng, Q., Liu, C.-H., Wang, Y., Wang, S., Chen, E., Wang, M., Zhou, T., Bai, L., Wu, D., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04197-6 · Cited by 26
A Sweet Connection? Fructose’s Role in Hepatocellular Carcinoma
Dewdney, B., Roberts, A. A., Qiao, L., George, J., & Hebbard, L. (2020) · Biomolecules · doi:10.3390/biom10040496 · Cited by 29
Huang, Y., Shen, Z., Huang, C., Teng, Y., Lin, C., & Tsai, T. (2021) · Antioxidants · doi:10.3390/antiox10040559 · Cited by 28
Ochoa-Rios, S. L., O'Connor, I. P., Kent, L. N., Clouse, J. M., Hadjiyannis, Y., Koivisto, C. S., Pécot, T., Angel, P. M., Drake, R. R., Leone, G. W., et al. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100225 · Cited by 26
Liang, J., Gu, L., Liu, X., Yan, X., Bi, X., Fan, X., Zhou, J., Lü, S., Luo, L., & Yin, Z. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00664-6 · Cited by 26
Cardoso-Lezama, I., Fuentes-Figueroa, M. Á., Ramos‐Tovar, E., Márquez-Quiroga, L. V., Ortiz‐Fernández, A., Vargas-Pozada, E. E., Arellanes‐Robledo, J., Tsutsumi, V., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115762 · Cited by 27
Elbadawy, M., Tanabe, K., Yamamoto, H., Ishihara, Y., Mochizuki, M., Abugomaa, A., Yamawaki, H., Kaneda, M., Usui, T., & Sasaki, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1243258 · Cited by 26
Novel therapeutics for portal hypertension and fibrosis in chronic liver disease
Guixé‐Muntet, S., Zhu, C., Xie, W., & Gracia‐Sancho, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107626 · Cited by 27
Bioactive Compounds from Brown Algae Alleviate Nonalcoholic Fatty Liver Disease: An Extensive Review
Wu, Y., Jin, X., Zhang, Y., Liu, J., Wu, M., & Tong, H. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06578 · Cited by 26
Yan, M., Li, H., Xu, S., Wu, J., Li, J., Xiao, C., Mo, C., & Ding, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411313 · Cited by 26
Maeso‐Díaz, R., Boyer‐Díaz, Z., Lozano, J. J., Ortega‐Ribera, M., Peralta, C., Bosch, J., & Gracia‐Sancho, J. (2019) · Cells · doi:10.3390/cells8091062 · Cited by 26
Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
Li, H., Liu, N., Li, J., Dong, B., Wang, M., Tan, J., Wang, X., Jiang, J., Lei, L., Li, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843872 · Cited by 24
Sakuma, T., Nakamura, M., Chiba, T., Iwanaga, T., Kan, M., Kojima, R., Ao, J., Ma, Y., Unozawa, H., Fujita, N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00807-6 · Cited by 24
Saha, S., Verma, R., Kumar, C., Kumar, B., Dey, A. K., Surjit, M., Mylavarapu, S. V. S., & Maiti, T. K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05003-4 · Cited by 22
Expression and functions of transient receptor potential channels in liver diseases
Wang, W., Liu, P., Zhang, Y., Li, Y., Zhu, M. X., Wang, J., & Ye, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.005 · Cited by 24
Liu, C., Jiang, W., Zeng, Q., Wu, D., Li, H., Zhou, L., Bai, L., & Tang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021297 · Cited by 24
Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine
Bakrania, A. K., To, J. C., Zheng, G., & Bhat, M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.07.012 · Cited by 26
Chen, D., Wang, Y., Yang, J., Ou, W., Lin, G., Zeng, Z., Lu, X., Chen, Z., Zou, L., Tian, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343755 · Cited by 25
NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
Fang, J., Celton‐Morizur, S., & Desdouets, C. (2023) · Cancers · doi:10.3390/cancers15143723 · Cited by 25
Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver
Gruevska, A., Leslie, J., Perpiñán, E., Maude, H., Collins, A., Johnson, S., Evangelista, L., Sabey, E., French, J., White, S., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156237 · Cited by 23
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 27
Preclinical mouse models of hepatocellular carcinoma: An overview and update
Gu, C. Y., & Lee, T. K. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113042 · Cited by 24
Bacil, G. P., Romualdo, G. R., Rodrigues, J., & Barbisan, L. F. (2023) · Food Research International · doi:10.1016/j.foodres.2023.113513 · Cited by 23
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 24
Steinberg, G. R., Gautam, J., Lally, J., Fayyazi, R., Grasset, E., Bhattacharya, D., Fidelito, G., Ahmadi, E., Townsend, L. K., Batchuluun, B., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.015 · Cited by 23
Self-citationLiu, J., Shi, Y., Peng, D., Wang, L., Yu, N., Wang, G., & Chen, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.842980 · Cited by 22
Characterizing the Mechanism Behind the Progression of NAFLD to Hepatocellular Carcinoma
Nahon, P., Allaire, M., Nault, J., & Paradis, V. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0017 · Cited by 23
Ichimura‐Shimizu, M., Omagari, K., Yamashita, M., & Tsuneyama, K. (2020) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaa107 · Cited by 21
Liu, Z., Wu, B., Liu, X., Wu, X., Du, J., Xia, G., Cai, J.-N., Zhu, H., Sheng, X., Zhang, M., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.80461 · Cited by 21
Zhu, Y., Chen, L., He, Y., Qin, L., Tan, D., Bai, Z., Song, Y., & Wang, Y.-H. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2202359 · Cited by 21
He, L., Huang, C., Wang, H., Yang, N., Zhang, J., Xu, L., Gu, T., Li, Z., & Chen, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161676 · Cited by 21
Tang, S., Wang, M., Peng, Y., Liang, Y., Lei, J., Tao, Q., Ming, T., Shen, Y., Zhang, C., Guo, J., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1290888 · Cited by 21
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 25
Self-citationThe effects of fructose and metabolic inhibition on hepatocellular carcinoma
Dewdney, B., Alanazy, M., Gillman, R., Walker, S. L., Wankell, M., Qiao, L., George, J., Roberts, A. A., & Hebbard, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-73653-5 · Cited by 20
Li, H., Liu, N.-N., Li, J.-R., Wang, M.-X., Tan, J.-L., Dong, B., Lan, P., Zhao, L.-M., Peng, Z.-G., & Jiang, J.-D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113083 · Cited by 20
Mitochondrial folate metabolism–mediated α-linolenic acid exhaustion masks liver fibrosis resolution
Gao, Y., Zheng, B., Xu, S., Zhao, Z., Liu, W., Wang, T., Yuan, M., Sun, X., Tan, Y., Xu, Q., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104909 · Cited by 21
Metadata
- Authors
- Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., & Friedman, S. L.
- Affiliations
- Tanabe Pharma Corporation (Japan) (JP)
- Icahn School of Medicine at Mount Sinai (US)
- Mount Sinai Hospital (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 69
- Issue
- 2
- Pages
- 385-395
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6054570
- OpenAlex
- W2790198401
- Cited by
- 583
- References
- 56
- Citations by year
- 2026: 65 · 2025: 86 · 2024: 90 · 2023: 91 · 2022: 93 · 2021: 62 · 2020: 52 · 2019: 34 · 2018: 10
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-01)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- NIH
- NIDDK (DK099558)
- European Commission (ERC-2014-AdG-671231)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, mouse model, Western diet, carbon tetrachloride, liver fibrosis, hepatocellular carcinoma, liver transcriptome, immune abnormalities, preclinical drug testing
- MeSH terms
- Animals, Carbon Tetrachloride, Disease Models, Animal, Fatty Liver, Inflammation, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Reproducibility of Results, Disease Progression, Gene Expression Profiling, Mice, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
